Neurosense Therapeutics Stock Market Value
| NRSN Stock | USD 0.96 0.02 2.13% |
| Symbol | Neurosense |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurosense Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurosense Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurosense Therapeutics.
| 10/28/2025 |
| 01/26/2026 |
If you would invest 0.00 in Neurosense Therapeutics on October 28, 2025 and sell it all today you would earn a total of 0.00 from holding Neurosense Therapeutics or generate 0.0% return on investment in Neurosense Therapeutics over 90 days. Neurosense Therapeutics is related to or competes with Neuraxis, Klotho Neurosciences, Collplant Biotechnologies, Exicure, Cadrenal Therapeutics, Enlivex Therapeutics, and Minerva Neurosciences. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments f... More
Neurosense Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurosense Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurosense Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 34.62 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 12.82 |
Neurosense Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurosense Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurosense Therapeutics' standard deviation. In reality, there are many statistical measures that can use Neurosense Therapeutics historical prices to predict the future Neurosense Therapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.25) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics January 26, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 4.49 | |||
| Coefficient Of Variation | (2,804) | |||
| Standard Deviation | 6.13 | |||
| Variance | 37.57 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 34.62 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 12.82 | |||
| Skewness | 0.8282 | |||
| Kurtosis | 1.49 |
Neurosense Therapeutics Backtested Returns
Neurosense Therapeutics has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. Neurosense Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurosense Therapeutics' Mean Deviation of 4.49, standard deviation of 6.13, and Risk Adjusted Performance of (0.02) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.91, which conveys possible diversification benefits within a given portfolio. Neurosense Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Neurosense Therapeutics is expected to follow. At this point, Neurosense Therapeutics has a negative expected return of -0.0315%. Please make sure to verify Neurosense Therapeutics' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Neurosense Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.57 |
Modest predictability
Neurosense Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Neurosense Therapeutics time series from 28th of October 2025 to 12th of December 2025 and 12th of December 2025 to 26th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurosense Therapeutics price movement. The serial correlation of 0.57 indicates that roughly 57.0% of current Neurosense Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.57 | |
| Spearman Rank Test | 0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurosense Stock
Moving against Neurosense Stock
| 0.66 | LYEL | Lyell Immunopharma | PairCorr |
| 0.62 | HLN | Haleon plc Aggressive Push | PairCorr |
| 0.58 | CAPR | Capricor Therapeutics | PairCorr |
| 0.57 | DBVT | DBV Technologies | PairCorr |
| 0.57 | CNOB | ConnectOne Bancorp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurosense Therapeutics Correlation, Neurosense Therapeutics Volatility and Neurosense Therapeutics Alpha and Beta module to complement your research on Neurosense Therapeutics. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Neurosense Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.